Affimed N.V.
AFMD · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.06 | 0.20 | 0.06 |
| FCF Yield | -22.93% | -21.43% | -26.64% | -30.72% |
| EV / EBITDA | -3.74 | -5.50 | -5.45 | -3.38 |
| Quality | ||||
| ROIC | -47.48% | -35.86% | -34.25% | -26.84% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 1.07 | 1.24 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -72.13% | -57.23% | -52.56% | -41.04% |
| Free Cash Flow Growth | 32.60% | 30.61% | 8.22% | -20.92% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | -0.26 | -0.10 | 0.99 |
| Interest Coverage | -53.49 | -49.22 | -53.82 | -50.57 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,637.87 | 3,341.10 | 3,505.94 | 1,160.85 |